Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ENSC | US
0.03
15.86%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.21
0.18
0.22
0.18
Ensysce Biosciences Inc. a clinical-stage pharmaceutical company engages in developing various prescription drugs for severe pain relief in opioid misuse abuse and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform an over-dose protection opioid prodrug technology. The company is developing PF614 a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases such as cystic fibrosis. It is also developing PF614 an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla California.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
118.8%1 month
115.1%3 months
142.5%6 months
114.6%-
-
1.38
0.25
0.16
-0.50
-
-
-24.22M
2.86M
2.86M
-
-1.08K
-
-62.90
-427.89
0.54
2.09
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.10
Range1M
0.17
Range3M
0.67
Rel. volume
11.66
Price X volume
2.88M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Galera Therapeutics Inc | GRTX | Biotechnology | 0.0555 | 3.07M | 2.78% | n/a | -0.87% |
NovaBay Pharmaceuticals Inc | NBY | Biotechnology | 0.6211 | 3.03M | -1.38% | n/a | -325.77% |
Hiru Corporation | HIRU | Biotechnology | 0.0016 | 3.02M | -15.79% | n/a | 263.27% |
SciSparc Ltd. Ordinary Shares | SPRC | Biotechnology | 0.29 | 3.00M | 26.53% | n/a | 1.00% |
Cyclacel Pharmaceuticals Inc | CYCC | Biotechnology | 1.32 | 2.84M | 15.79% | n/a | 0.50% |
Phio Pharmaceuticals Corp | PHIO | Biotechnology | 3.18 | 2.74M | 9.28% | n/a | 0.00% |
Salarius Pharmaceuticals Inc | SLRX | Biotechnology | 1.82 | 2.62M | -9.45% | n/a | 0.00% |
ZVSA | ZVSA | Biotechnology | 2.3 | 2.47M | 0.00% | 0.00 | 0.00% |
Dermata Therapeutics Inc. Common Stock | DRMA | Biotechnology | 1.56 | 2.36M | -3.11% | n/a | 0.00% |
Allarity Therapeutics Inc. Common Stock | ALLR | Biotechnology | 1.63 | 2.30M | -5.78% | n/a | 6.68% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.50 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 1.38 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 142.50 | 72.80 | Riskier |
Debt to Equity | 0.25 | -1.23 | Expensive |
Debt to Assets | 0.16 | 0.25 | Cheaper |
Market Cap | 2.86M | 3.66B | Emerging |